ADPT

SEC source: 0001209191-21-030752 · doc4.xml · derivative · entry 4

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,325

Underlying: Common Stock · 3,895 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F4 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-21-030752 · doc4.xml · nonDerivative · entry 3

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,360

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $36.50 to 37.09, inclusive.

SEC source: 0001209191-21-030752 · doc4.xml · nonDerivative · entry 2

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,060

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $35.43 to 36.34, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-21-030752 · doc4.xml · nonDerivative · entry 1

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,255

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

SEC source: 0001209191-21-029626 · doc4.xml · derivative · entry 7

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,042

Underlying: Common Stock · 1,354 shares

Expires 2030-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020.

F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on February 13, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-029626 · doc4.xml · derivative · entry 6

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,480

Underlying: Common Stock · 1,770 shares

Expires 2028-04-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020.

F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-029626 · doc4.xml · derivative · entry 5

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 1,042 shares

Expires 2029-04-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020.

F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on April 23, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-029626 · doc4.xml · nonDerivative · entry 4

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,036

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $41.68 to 42.14, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-21-029626 · doc4.xml · nonDerivative · entry 3

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,202

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020.

SEC source: 0001209191-21-029626 · doc4.xml · nonDerivative · entry 2

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,848

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020.

SEC source: 0001209191-21-029626 · doc4.xml · nonDerivative · entry 1

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,078

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020.

SEC source: 0001209191-21-028051 · doc4.xml · derivative · entry 13

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,220

Underlying: Common Stock · 7,790 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F9 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-21-028051 · doc4.xml · nonDerivative · entry 10

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,360

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F8 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $43.38 to 43.85, inclusive.

SEC source: 0001209191-21-028051 · doc4.xml · nonDerivative · entry 9

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,870

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F7 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $42.37 to 43.34, inclusive.

SEC source: 0001209191-21-028051 · doc4.xml · nonDerivative · entry 8

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,150

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

SEC source: 0001209191-21-028051 · doc4.xml · derivative · entry 12

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 148,010

Underlying: Common Stock · 7,790 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F9 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-21-028051 · doc4.xml · nonDerivative · entry 7

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,360

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $41.48 to 42.17, inclusive.

SEC source: 0001209191-21-028051 · doc4.xml · nonDerivative · entry 6

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,560

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $40.44 to 41.43, inclusive.

SEC source: 0001209191-21-028051 · doc4.xml · nonDerivative · entry 5

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,650

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $39.40 to 40.39, inclusive.

SEC source: 0001209191-21-028051 · doc4.xml · nonDerivative · entry 4

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,150

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

SEC source: 0001209191-21-028051 · doc4.xml · derivative · entry 11

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 155,800

Underlying: Common Stock · 11,685 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F9 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-21-028051 · doc4.xml · nonDerivative · entry 3

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,360

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $40.90 to 41.69, inclusive.

SEC source: 0001209191-21-028051 · doc4.xml · nonDerivative · entry 2

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,360

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $39.90 to 40.77, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-21-028051 · doc4.xml · nonDerivative · entry 1

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,045

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

SEC source: 0001209191-21-027852 · doc4.xml · derivative · entry 3

Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, T-Detect

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,647

Underlying: Common Stock · 1,301 shares

Expires 2030-03-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020.

F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 18, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-027852 · doc4.xml · nonDerivative · entry 2

Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, T-Detect

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,158

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020.

SEC source: 0001209191-21-027852 · doc4.xml · nonDerivative · entry 1

Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, T-Detect

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,459

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020.

SEC source: 0001209191-21-027122 · doc4.xml · derivative · entry 4

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 153,000

Underlying: Common Stock · 2,000 shares

Expires 2029-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020.

F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on May 6, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-027122 · doc4.xml · nonDerivative · entry 2

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,604

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020.

SEC source: 0001209191-21-027122 · doc4.xml · nonDerivative · entry 1

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,604

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020.

SEC source: 0001209191-21-027121 · doc4.xml · derivative · entry 3

BALDO LANCE · CIK 0001780773 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 339,250

Underlying: Common Stock · 2,000 shares

Expires 2029-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2020 and modified on March 3, 2021.

F2 · derivative.exercise_date: The options vested with respect to 1/4 of the shares on May 6, 2020, with 1/48 of the shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-027121 · doc4.xml · nonDerivative · entry 2

BALDO LANCE · CIK 0001780773 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,894

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2020 and modified on March 3, 2021.

SEC source: 0001209191-21-027121 · doc4.xml · nonDerivative · entry 1

BALDO LANCE · CIK 0001780773 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,894

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2020 and modified on March 3, 2021.

SEC source: 0001209191-21-027123 · doc4.xml · derivative · entry 3

GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,500

Underlying: Common Stock · 4,500 shares

Expires 2029-04-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020.

F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 28, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-027123 · doc4.xml · nonDerivative · entry 2

GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,504

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020.

SEC source: 0001209191-21-027123 · doc4.xml · nonDerivative · entry 1

GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,004

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020.

SEC source: 0001209191-21-026181 · doc4.xml · nonDerivative · entry 8

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,748,461

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020.

SEC source: 0001209191-21-026181 · doc4.xml · nonDerivative · entry 7

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,748,561

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020.

F8 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $42.70 to 43.68, inclusive.

SEC source: 0001209191-21-026181 · doc4.xml · nonDerivative · entry 6

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,750,518

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020.

F7 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $41.64 to 42.60, inclusive.

SEC source: 0001209191-21-026181 · doc4.xml · nonDerivative · entry 5

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,753,461

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020.

F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $41.01 to 41.85, inclusive.

SEC source: 0001209191-21-026181 · doc4.xml · nonDerivative · entry 4

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,754,561

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020.

F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $40.06 to 40.93, inclusive.

SEC source: 0001209191-21-026183 · doc4.xml · derivative · entry 7

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 10,000 shares

Expires 2025-08-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

F4 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-21-026183 · doc4.xml · nonDerivative · entry 5

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,604

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

SEC source: 0001209191-21-026183 · doc4.xml · nonDerivative · entry 4

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,410

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $41.26 to 41.98, inclusive.

SEC source: 0001209191-21-026183 · doc4.xml · nonDerivative · entry 3

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,604

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

SEC source: 0001209191-21-026200 · doc4.xml · nonDerivative · entry 1

ADAMS R MARK · CIK 0001808905 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,018

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001209191-21-026181 · doc4.xml · nonDerivative · entry 3

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,758,461

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020.

F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $42.92 to 43.43, inclusive.

SEC source: 0001209191-21-026181 · doc4.xml · nonDerivative · entry 2

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,759,661

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $41.90 to 42.88, inclusive.

SEC source: 0001209191-21-026181 · doc4.xml · nonDerivative · entry 1

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,761,861

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $40.82 to 41.55, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-21-026183 · doc4.xml · derivative · entry 6

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 10,000 shares

Expires 2025-08-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

F4 · derivative.exercise_date: The option is fully vested and exercisable.